Form 4: Immuneering Corp Executive Michael Bookman Reprices Stock Options

Michael Bookman, Chief Legal Officer and Secretary of Immuneering Corp, had his stock options repriced to $3.01 per share on May 21, 2024, as approved by the Issuer's Board of Directors.

Summary

• On May 21, 2024, Immuneering Corp's Board of Directors approved the repricing of stock options held by Michael Bookman, the company's Chief Legal Officer and Secretary.
• The exercise price for these options was adjusted to $3.01 per share.
• The repricing affects options with original exercise prices of $15.00, $9.66, $4.25, and $6.09.
• A total of 384,416 options were repriced.
• If Bookman is terminated for cause, resigns (except due to death or disability), or elects to exercise the repriced options before June 30, 2025, the exercise price will revert to the original price, unless there is a change of control of the Issuer.
• The options vest over time, with varying commencement dates and vesting schedules.

Sentiment

Score: 5

Explanation: The document itself is neutral, simply reporting a transaction. The sentiment depends on whether one views the repricing as a positive incentive for management or a sign of past underperformance.

Positives

• The repricing of options may incentivize Michael Bookman to remain with the company and contribute to its success.
• The repricing could make the options more attractive to Bookman, potentially aligning his interests with those of the shareholders.

Risks

• If Bookman leaves the company before June 30, 2025, under certain conditions, the exercise price of the options will revert to the original, higher prices, potentially negating the benefit of the repricing.
• The repricing could be perceived negatively by shareholders if it is seen as unduly benefiting an executive at their expense.

Industry Context

Option repricing is a tool companies sometimes use to re-incentivize employees when the stock price has fallen significantly, making existing options less valuable. This is common in the biotech industry, where stock prices can be volatile due to the long development timelines and regulatory hurdles associated with bringing new drugs to market.

Comparison to Industry Standards

• Option repricing is a relatively common practice, especially in volatile industries like biotechnology.
• Many companies, such as Amgen, Biogen, and Gilead, have used similar strategies to retain and motivate key employees during periods of stock price decline.
• The specific terms of the repricing, such as the new exercise price and vesting schedule, are generally tailored to the individual circumstances of the company and the employee.

Stakeholder Impact

• Shareholders may view the option repricing as a positive or negative development, depending on their perspective on executive compensation and company performance.
• Employees may see the repricing as a positive sign that the company is committed to retaining talent.
• The repricing has no direct impact on customers, suppliers, or creditors.

Key Dates